PTGX

Protagonist Therapeutics Stock Analysis

AI Rating

Good
  • Quality9/10
  • Growth↓ 0/10
  • Momentum↑ 8/10
Protagonist Therapeutics sales and earnings growth
PTGX Growth
Low
  • Revenue Y/Y↓ -35.39%
  • EPS Y/Y↓ -73.36%
  • FCF Y/Y↓ -72.21%
Protagonist Therapeutics gross and profit margin trends
PTGX Profitability
Neutral
  • Gross margin ↑ 100.00%
  • EPS margin↑ 21.90%
  • ROIC↓ 8.50%
Protagonist Therapeutics net debt vs free cash flow
PTGX Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Protagonist Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗